Literature DB >> 11640869

Cytogenetics of chronic myeloid leukaemia.

A Chase1, B J Huntly, N C Cross.   

Abstract

The standard Philadelphia (Ph) translocation t(9;22), its variants and a proportion of Ph-negative cases are positive for the BCR-ABL fusion gene, as determined by molecular analysis. Extensive deletions of chromosome 9 and 22 derived sequences around the translocation breakpoints on the derivative 9 are seen in 10-30% of patients at diagnosis and may confer a worse prognosis. Additional cytogenetic changes can occur in the few months before or during disease progression and are often specific for blast morphology; however, the molecular basis of the most common additional cytogenetic abnormalities is largely unknown. Cytogenetics is important for monitoring patient response to treatment but is increasingly being replaced by the more sensitive and less invasive techniques of RT-PCR and FISH. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11640869     DOI: 10.1053/beha.2001.0154

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  6 in total

1.  Monitoring response and resistance to treatment in chronic myeloid leukemia.

Authors:  S Assouline; J H Lipton
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

2.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

Review 3.  BCR-ABL-negative chronic myeloid leukemia.

Authors:  Sonja Burgstaller; Andreas Reiter; Nicholas C P Cross
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

4.  Effects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells.

Authors:  Fu-Lan Yang; Fang-Zhi Chen; Xin-Xing Wan; Xi Zhou; Mei-Juan Zhou; Han-Chun Chen; Jun-Jiang Fu; Dian-Zheng Zhang
Journal:  Biomed Res Int       Date:  2015-09-01       Impact factor: 3.411

5.  Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic Myelogenous Leukemia Patients.

Authors:  Soheila Manaflouyan Khajehmarjany; Seyed Ali Rahmani; Seyed Hadi Chavoshi; Ali Esfahani; Ali Akbar Movassaghpour Akbari
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

6.  Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.

Authors:  Vlad Moisoiu; Patric Teodorescu; Lorand Parajdi; Sergiu Pasca; Mihnea Zdrenghea; Delia Dima; Radu Precup; Ciprian Tomuleasa; Simona Soverini
Journal:  Front Oncol       Date:  2019-09-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.